Stake logo

STIM

NEURONETICS INC

About STIM

Neuronetics, Inc. is a commercial stage medical technology company. The Company is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

Buy US stocks in Australia starting with STIM. Open an account and start investing today!

Market Capitalisation

$158.70M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

0

High today

$6.09

Low today

$5.72

Open price

$0.00

52-week high

$6.95

52-week low

$1.98


STIM FAQs

One share of NEURONETICS INC is valued at $5.81.

The ticker symbol for NEURONETICS INC is STIM.

To buy STIM stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in STIM

As of 27/01/2023 NEURONETICS INC has a market cap of $159M.

The NEURONETICS INC 52-week high stock price is $6.95.

The NEURONETICS INC 52-week low stock price is $1.98.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.